TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Sees Large Decline in Short Interest

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 18,600 shares, a decline of 53.5% from the March 31st total of 40,000 shares. Based on an average daily volume of 588,800 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.3% of the company’s stock are short sold.

TransCode Therapeutics Price Performance

Shares of RNAZ traded up $0.02 during trading hours on Friday, hitting $0.55. The stock had a trading volume of 725,735 shares, compared to its average volume of 389,178. TransCode Therapeutics has a 12 month low of $0.42 and a 12 month high of $356.00. The firm has a market capitalization of $3.19 million, a PE ratio of 0.00 and a beta of -0.35. The stock has a fifty day moving average price of $0.64 and a 200 day moving average price of $5.31.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating on shares of TransCode Therapeutics in a research note on Tuesday, April 16th.

Institutional Trading of TransCode Therapeutics

An institutional investor recently raised its position in TransCode Therapeutics stock. Sabby Management LLC increased its position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 32.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 250,309 shares of the company’s stock after acquiring an additional 61,872 shares during the period. Sabby Management LLC owned about 12.33% of TransCode Therapeutics worth $126,000 at the end of the most recent reporting period.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.